ATE219105T1 - Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe - Google Patents

Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe

Info

Publication number
ATE219105T1
ATE219105T1 AT95916676T AT95916676T ATE219105T1 AT E219105 T1 ATE219105 T1 AT E219105T1 AT 95916676 T AT95916676 T AT 95916676T AT 95916676 T AT95916676 T AT 95916676T AT E219105 T1 ATE219105 T1 AT E219105T1
Authority
AT
Austria
Prior art keywords
antibodies
monoclonal antibodies
antibodies against
against hiv
mixtures
Prior art date
Application number
AT95916676T
Other languages
English (en)
Inventor
Hermann Katinger
Andrea Buchacher
Wolfgang Ernst
Claudia Ballaun
Martin Purtscher
Alexandra Trkola
Renate Predl
Christine Schmatz
Annelies Klima
Franz Steindl
Thomas Muster
Original Assignee
Polymun Scient Immunbio Forsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polymun Scient Immunbio Forsch filed Critical Polymun Scient Immunbio Forsch
Application granted granted Critical
Publication of ATE219105T1 publication Critical patent/ATE219105T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95916676T 1995-04-19 1995-04-19 Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe ATE219105T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1995/001481 WO1996033219A1 (en) 1995-04-19 1995-04-19 Monoclonal antibodies against hiv-1 and vaccines made thereof
CA002218515A CA2218515C (en) 1995-04-19 1995-04-19 Monoclonal antibodies against hiv-1 and vaccines made thereof

Publications (1)

Publication Number Publication Date
ATE219105T1 true ATE219105T1 (de) 2002-06-15

Family

ID=25679733

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95916676T ATE219105T1 (de) 1995-04-19 1995-04-19 Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe

Country Status (11)

Country Link
US (1) US5911989A (de)
EP (1) EP0822941B1 (de)
AT (1) ATE219105T1 (de)
AU (1) AU2308595A (de)
BR (1) BR9510575A (de)
CA (1) CA2218515C (de)
DE (1) DE69527089T2 (de)
ES (1) ES2178672T3 (de)
MX (1) MX9708008A (de)
WO (1) WO1996033219A1 (de)
ZA (1) ZA962629B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6866000A (en) * 1999-08-31 2001-03-26 Asahi Glass Company Limited Process for producing a vic-dichloro acid fluoride
EP1418940A4 (de) * 2000-03-02 2006-09-20 Univ Emory Dna expressionsvektoren und verwendungsverfahren
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
DE60234018D1 (de) * 2001-03-08 2009-11-26 Univ Emory Mva-exprimierende modifizierte hiv-envelope-, gag-, und pol-gene
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2504755C (en) * 2002-10-11 2010-12-14 University Of Maryland Biotechnology Institute Carbohydrate-based synthetic vaccines for hiv
CA2525370A1 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
EP1868651A4 (de) 2005-04-12 2010-10-06 Univ Duke Verfahren zur induktion von neutralisierenden antikörpern gegen das hiv-virus
US20080138351A1 (en) * 2006-08-02 2008-06-12 United Therapeutics Corporation Liposome treatment of viral infections
AU2008239628B2 (en) 2007-04-13 2014-01-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2331133A4 (de) * 2008-09-05 2012-09-12 Univ Duke Anti-lipid-antikörper
US20110305700A1 (en) * 2008-09-05 2011-12-15 Duke University Anti-lipid antibodies
US20100093563A1 (en) * 2008-09-22 2010-04-15 Robert Anthony Williamson Methods and vectors for display of molecules and displayed molecules and collections
US20100081575A1 (en) * 2008-09-22 2010-04-01 Robert Anthony Williamson Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
TR201910848T4 (tr) 2009-02-13 2019-08-21 Immunomedics Inc İntraselüler olarak ayrilabi̇len bi̇r bağa sahi̇p i̇mmunokonjugatlar
WO2010109330A2 (en) 2009-03-27 2010-09-30 University Of Oxford Cholesterol level lowering liposomes
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP3187585A1 (de) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
CN107115526A (zh) 2011-05-02 2017-09-01 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
CN109513003A (zh) 2012-08-14 2019-03-26 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
KR20230078823A (ko) 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN112759650A (zh) 2014-04-03 2021-05-07 Igm生物科学股份有限公司 修饰的j链
WO2015197919A1 (en) 2014-06-25 2015-12-30 Glykos Finland Oy Antibody drug conjugates binding to high-mannose n-glycan
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3313443B9 (de) 2015-06-25 2023-10-04 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
EP3316885B1 (de) 2015-07-01 2021-06-23 Immunomedics, Inc. Antikörper-sn-38-immunkonjugate mit einem cl2a-linker
EP3824903A1 (de) 2015-09-30 2021-05-26 IGM Biosciences Inc. Bindungsmoleküle mit modifizierter j-kette
CN108463472A (zh) 2015-09-30 2018-08-28 Igm生物科学有限公司 具有修饰的j-链的结合分子
WO2017093985A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
CN118043080A (zh) 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
CN117881431A (zh) 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
WO2023103854A1 (zh) 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761470A (en) * 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5087557A (en) * 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
JPH02502251A (ja) * 1987-11-13 1990-07-26 ヘルマン　カーティンガー ヒトのモノクローン性抗ｈｉｖ‐１‐抗体
IL101201A0 (en) * 1991-03-11 1992-11-15 Idec Pharma Corp Methods for selecting antibody reagents,anti-idiotype antibodies and aids vaccine formulations
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
DE69311764T2 (de) * 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
EP0725825B1 (de) * 1993-09-11 2001-02-21 Polymun Scientific Immunbiologische Forschung GmbH Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren

Also Published As

Publication number Publication date
EP0822941B1 (de) 2002-06-12
MX9708008A (es) 1998-03-31
DE69527089T2 (de) 2003-01-02
CA2218515A1 (en) 1996-10-24
ZA962629B (en) 1997-10-02
CA2218515C (en) 2008-10-07
WO1996033219A1 (en) 1996-10-24
DE69527089D1 (de) 2002-07-18
EP0822941A1 (de) 1998-02-11
AU2308595A (en) 1996-11-07
BR9510575A (pt) 1998-12-15
ES2178672T3 (es) 2003-01-01
US5911989A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
ATE219105T1 (de) Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
CA2310888A1 (en) Monoclonal human natural antibodies
ATE185351T1 (de) Ein mit hiv-1-glykoprotein reagierender menschlicher monoklonaler igg-1-antikörper und verwendungsmethode
DK0552296T3 (da) Monoklonale antistoffer fra mus
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
DE69332643D1 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
IN2012DN00313A (de)
DE69327620D1 (de) Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
DE69626423T2 (de) Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
ATE348882T1 (de) Humanisierte monoklonale integrin antikörper
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
ATE256148T1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
WO2023039613A3 (en) Lilrb2-specific monoclonal antibodies and methods of their use
TH39342A (th) โมโนโคลนอลแอนติบอดีต่อ hiv-1 และวัคซีนที่สร้างจากมัน
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification